|
Post by goyocafe on Dec 23, 2016 15:19:58 GMT -5
It makes no sense for SNY to purchase MNKD's old stash of insulin. However, SNY required MNKD to enter in to a now onerous contract with AMPH, so it does make sense for SNY to take some of that insulin off MNKD's hands. IIRC they paid $10MM for the insulin, but delivery was not a part of the settlement. Could be wrong.
|
|
|
Post by liane on Dec 23, 2016 15:51:14 GMT -5
My memory is that they paid for some insulin that would be delivered and some that would not.
|
|
|
Post by falconquest on Dec 23, 2016 16:13:55 GMT -5
It makes no sense for SNY to purchase MNKD's old stash of insulin. However, SNY required MNKD to enter in to a now onerous contract with AMPH, so it does make sense for SNY to take some of that insulin off MNKD's hands. I hate to say it about this guy Liane but, I told you so. This guy's conjecture, innuendo, false analogies and unrelated links between events will drive a person crazy trying to decipher. After while it causes people to give up and he just keeps posting his false comments. You're the moderator, I guess it's up to you what you do with it.
|
|
|
Post by surplusvalue on Dec 23, 2016 18:57:59 GMT -5
Mike: You've been here since Dec 18th and already created two threads about Sanofi and MNKD. Sanofi clearly stated through their agents to the press in January, when they cancelled the partnership with MNKD, that Afrezza couldnt be commercialized. End of story. The legal repercussions of Sanofi coming back would be catastrophic. You're like the guy whose old girlfriend broke up with him in high school and you never were able to accept it or get over it. It's over. Time to move on. If you want to live in fantasy island, that's fine ...but do everyone else here a favour and don't post about it. The very best to you for the holidays and new year.
|
|
|
Post by slugworth008 on Dec 23, 2016 19:52:37 GMT -5
Seems strange that SNY just gives up $75mm to MNKD which is a good amount of "buy me some more time $$" and also purchases $10mm of insulin which has to be inhaled insulin. SNY can use that inhaled insulin in their Frankfort Germany facility "for something". SNY is cutting their diabetes sales force at a time when Vdex is coming out of their coma and remember that Dexcom now has FDA approval for their new small, disposable CGM devices. Seems strange that Bill at Vdex owns a hair salon and is an attorney who has interest in the world of diabetes too.....that's peculiar......hair, law and diabetes are an unusual combination unless he opens a sandwich shop too. Or maybe, just maybe the attorney element of Bill's ventures is getting things done for his "client" who continues to hide in the shadows. Well, that SNY + Google partnership remains in tact. Ya, these are indeed things to ponder as the PPS and RXs move together in harmony like the two front wheels of Bill's 500SL. Mike I feel your pain but it seems that being a longtime MNKD long has made you insane. And that's completely understandable.
|
|
|
Post by sophie on Dec 23, 2016 20:29:45 GMT -5
Seems strange that SNY just gives up $75mm to MNKD which is a good amount of "buy me some more time $$" and also purchases $10mm of insulin which has to be inhaled insulin. SNY can use that inhaled insulin in their Frankfort Germany facility "for something". SNY is cutting their diabetes sales force at a time when Vdex is coming out of their coma and remember that Dexcom now has FDA approval for their new small, disposable CGM devices. Seems strange that Bill at Vdex owns a hair salon and is an attorney who has interest in the world of diabetes too.....that's peculiar......hair, law and diabetes are an unusual combination unless he opens a sandwich shop too. Or maybe, just maybe the attorney element of Bill's ventures is getting things done for his "client" who continues to hide in the shadows. Well, that SNY + Google partnership remains in tact. Ya, these are indeed things to ponder as the PPS and RXs move together in harmony like the two front wheels of Bill's 500SL. Just so I understand you correctly- Sanofi has this huge wad of cash backing them up in Google. Their response to enormous stack of cash is to save money by slashing their workforce while their competitors are developing superior products? Instead of working harder to peddle their inferior product, they decide to allow their enemies to invade and claim their previously held territory? And all of this because one location just opened up that no one but investors has heard about? This one location that hasn't yet helped increase the script counts from the mean of the past 6 months? Bill just sounds like an intelligent individual who has a diversified portfolio. I'm not quite sure why you're bragging about having the most shares of anyone on here. It also means you've probably lost the most money. I'm not sure that's something to brag about. Good investing is diversified investing. Probably why Bill has a SL500. Falcon, I don't mind if the moderators allow him to stand on boxes and shout. If they allow him to be the village idiot, I hope they at least allow us to throw our tomatoes at him as well.
|
|
|
Post by falconquest on Dec 23, 2016 21:38:05 GMT -5
Seems strange that SNY just gives up $75mm to MNKD which is a good amount of "buy me some more time $$" and also purchases $10mm of insulin which has to be inhaled insulin. SNY can use that inhaled insulin in their Frankfort Germany facility "for something". SNY is cutting their diabetes sales force at a time when Vdex is coming out of their coma and remember that Dexcom now has FDA approval for their new small, disposable CGM devices. Seems strange that Bill at Vdex owns a hair salon and is an attorney who has interest in the world of diabetes too.....that's peculiar......hair, law and diabetes are an unusual combination unless he opens a sandwich shop too. Or maybe, just maybe the attorney element of Bill's ventures is getting things done for his "client" who continues to hide in the shadows. Well, that SNY + Google partnership remains in tact. Ya, these are indeed things to ponder as the PPS and RXs move together in harmony like the two front wheels of Bill's 500SL. Just so I understand you correctly- Sanofi has this huge wad of cash backing them up in Google. Their response to enormous stack of cash is to save money by slashing their workforce while their competitors are developing superior products? Instead of working harder to peddle their inferior product, they decide to allow their enemies to invade and claim their previously held territory? And all of this because one location just opened up that no one but investors has heard about? This one location that hasn't yet helped increase the script counts from the mean of the past 6 months? Bill just sounds like an intelligent individual who has a diversified portfolio. I'm not quite sure why you're bragging about having the most shares of anyone on here. It also means you've probably lost the most money. I'm not sure that's something to brag about. Good investing is diversified investing. Probably why Bill has a SL500. Falcon, I don't mind if the moderators allow him to stand on boxes and shout. If they allow him to be the village idiot, I hope they at least allow us to throw our tomatoes at him as well. Simply.........Lol!
|
|
|
Post by mango on Dec 23, 2016 21:55:28 GMT -5
Seems strange that SNY just gives up $75mm to MNKD which is a good amount of "buy me some more time $$" and also purchases $10mm of insulin which has to be inhaled insulin. SNY can use that inhaled insulin in their Frankfort Germany facility "for something". SNY is cutting their diabetes sales force at a time when Vdex is coming out of their coma and remember that Dexcom now has FDA approval for their new small, disposable CGM devices. Seems strange that Bill at Vdex owns a hair salon and is an attorney who has interest in the world of diabetes too.....that's peculiar......hair, law and diabetes are an unusual combination unless he opens a sandwich shop too. Or maybe, just maybe the attorney element of Bill's ventures is getting things done for his "client" who continues to hide in the shadows. Well, that SNY + Google partnership remains in tact. Ya, these are indeed things to ponder as the PPS and RXs move together in harmony like the two front wheels of Bill's 500SL. Just so I understand you correctly- Sanofi has this huge wad of cash backing them up in Google. Their response to enormous stack of cash is to save money by slashing their workforce while their competitors are developing superior products? Instead of working harder to peddle their inferior product, they decide to allow their enemies to invade and claim their previously held territory? And all of this because one location just opened up that no one but investors has heard about? This one location that hasn't yet helped increase the script counts from the mean of the past 6 months? Bill just sounds like an intelligent individual who has a diversified portfolio. I'm not quite sure why you're bragging about having the most shares of anyone on here. It also means you've probably lost the most money. I'm not sure that's something to brag about. Good investing is diversified investing. Probably why Bill has a SL500. Falcon, I don't mind if the moderators allow him to stand on boxes and shout. If they allow him to be the village idiot, I hope they at least allow us to throw our tomatoes at him as well. My DD does not show William (Bill) McCullough as actually having a diversified business portfolio. Actually, quite the opposite. Samson Hair Restoration was established in 2002. This is his only major venture besides Vdex. Also, Mr. McCulloughs ideology correlates with Mr. Mann's, which is apparent through his SHR website.
|
|
|
Post by mnkdfann on Dec 23, 2016 22:24:56 GMT -5
My 'special snowflake' detector is going off like an alert for a five alarm fire.
|
|
|
Post by mango on Dec 23, 2016 22:32:40 GMT -5
My 'special snowflake' detector is going off like an alert for a five alarm fire. No one is making you hold the stock. Sell away, and don't feel the need to make yourself feel better anymore!
|
|
|
Post by kc on Dec 24, 2016 0:30:24 GMT -5
|
|
|
Post by mnholdem on Dec 24, 2016 1:20:01 GMT -5
Under the terms of the Settlement Agreement, Sanofi has agreed to purchase $10.2 million of insulin from the Company by December 3, 2016 under the insulin put option (the “Insulin Put Option”) pursuant to the Supply Agreement (the “Supply Agreement”), dated August 11, 2014, by and between the Company and Sanofi, as assignee of Sanofi-Aventis Deutschland GmbH (“Sanofi GmbH”). In addition, Sanofi has agreed to make a cash payment of $30.6 million to the Company within 60 days after the Effective Date as acceleration and in replacement of all other payments that Sanofi would otherwise have been required to make in the future pursuant to the Insulin Put Option, without the Company being required to deliver any insulin for such payment. The Company has also been relieved of its obligation to pay Sanofi $0.5 million in previously uncharged costs pursuant to the License and Collaboration Agreement (the “License and Collaboration Agreement”), dated August 11, 2014, by and among the Company, Sanofi GmbH, BV and TICV. SEC filing: investors.mannkindcorp.com/secfiling.cfm?filingID=1193125-16-764506&CIK=899460
|
|
|
Post by mnholdem on Dec 24, 2016 1:32:42 GMT -5
I am curious, mikesmilitaria , whether you find the section in the SEC filing giving Amphastar a say in participating in sales in China to be a more worthy "thing to ponder" than Sanofi's post-Afrezza activities with Alphabet/Verily: Pursuant to the Amendment, the term of the Amphastar Agreement was extended from December 1, 2019 to December 31, 2023. In addition, the delivery schedule was modified to provide that Amphastar will ship €2.7 million of insulin to the Company in the fourth quarter of 2017, €8.9 million in 2018, €11.6 million in 2019, €15.5 million in 2020 and in 2021, and €19.4 million in 2022 and in 2023. The Company also granted Amphastar a right of first refusal to participate in the development and commercialization of Afrezza in China through a potential business collaboration.In your opinion is this section, specifically the wording "through a potential business collaboration" suggesting that there may be a China deal/collaboration in the works?
|
|
|
Post by brotherm1 on Dec 24, 2016 1:38:51 GMT -5
Mike: You've been here since Dec 18th and already created two threads about Sanofi and MNKD. Sanofi clearly stated through their agents to the press in January, when they cancelled the partnership with MNKD, that Afrezza couldnt be commercialized. End of story. The legal repercussions of Sanofi coming back would be catastrophic. You're like the guy whose old girlfriend broke up with him in high school and you never were able to accept it or get over it. It's over. Time to move on. If you want to live in fantasy island, that's fine ...but do everyone else here a favour and don't post about it. The very best to you for the holidays and new year. [ "Sanofi clearly stated through their agents to the press in January, when they cancelled the partnership with MNKD, that Afrezza could not be commercialized" I've read numerous articles about the partnership cancellation, but none saying what you just said. Would you please provide a link to an article where Sanofi said this? Thanks in advance.
|
|
|
Post by careful2invest on Dec 24, 2016 2:20:45 GMT -5
Mike: You've been here since Dec 18th and already created two threads about Sanofi and MNKD. Sanofi clearly stated through their agents to the press in January, when they cancelled the partnership with MNKD, that Afrezza couldnt be commercialized. End of story. The legal repercussions of Sanofi coming back would be catastrophic. You're like the guy whose old girlfriend broke up with him in high school and you never were able to accept it or get over it. It's over. Time to move on. If you want to live in fantasy island, that's fine ...but do everyone else here a favour and don't post about it. The very best to you for the holidays and new year. [ "Sanofi clearly stated through their agents to the press in January, when they cancelled the partnership with MNKD, that Afrezza could not be commercialized" I've read numerous articles about the partnership cancellation, but none saying what you just said. Would you please provide a link to an article where Sanofi said this? Thanks in advance. Brotherm, Not to speak for surplus, but until he/she responds... I think that was paraphrasing what Sanofi said, not a direct quote, because I read them as well. If my memory serves me correctly, Sanofi said that AFREZZA could not be commercially successful, or was not commercially viable. Words to that effect nonetheless! Hopefully someone finds the exact verbiage to put it to rest. However, given the promise that AFREZZA has to offer, it made no sense then or now for Sanofi or some other BP not to jump all over AFREZZA. No sense at all! Strange things happen in the business world. Think if Mike ends up being right? Verily still has an agreement with Sanofi, yet Sanofi no longer has inhaleable insulin! MNKD does! Something does not add up! Whomever ends up marketing AFREZZA and finally making it a success, hopefully, I will still be around to reap the benefits. That goes for all of us that invested in and believe in AFREZZA! GLTA TRUE LONGS!
|
|